Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Exelixis cashes in on a hot therapeutic drug target, showing that an R&D-focused biotech can succeed in the marketplace.
You may also be interested in...
Gilead Springs Further Into Oncology With Calistoga Acquisition
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
Gilead Springs Further Into Oncology With Calistoga Acquisition
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
As Exelixis Reigns In Spending, It Looks To Offload Early-Stage Assets
Management elaborates on plans to scale down early discovery and drug development to focus resources on its three lead partnered drugs.